Bayer has licensed lipid nanoparticle (LNP) technology from Acuitas Therapeutics to develop in vivo gene editing and protein replacement programs in the liver.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,